Ischemic colitis can range from mild inflammation to life-threatening damage. Early diagnosis and tailored care make all the ...

Johnson & Johnson (NYSE:JNJ) recently presented promising data on TREMFYA® for ulcerative colitis and Crohn's disease, ...

Johnson & Johnson announces new data from Tremfya phase 3 QUASAR LTE study in adults with moderately-to-severely active ulcerative colitis: San Diego, California Tuesday, May 6, 2 ...

Guselkumab significantly improves clinical remission rates in patients with active ulcerative colitis, according to phase 3 data.

Drug major Johnson & Johnson (JNJ) announced Monday positive new data from the Phase 3 ASTRO study evaluating TREMFYA (guselkumab) subcutaneous (SC) induction therapy ...

In 2021, Sly, biochemistry professor Harry Brumer, and a group of other researchers at the UBC developed GlycoCage, a ...

AbbVie snagged yet another spot among April’s highest TV ad spenders, as its Vraylar jumped two spots to eighth place with a ...

New long-term extension data from the Phase IIb/III QUASAR trial demonstrate that Tremfya (guselkumab) maintains durable ...

Johnson & Johnson (NYSE: JNJ) today announced new data from the TREMFYA® (guselkumab) Phase 3 QUASAR long-term extension (LTE) study in adults with moderately-to-severely active ulcerative colitis (UC ...

That has to be a back-and-forth discussion. The second thing is, given that we have all of these therapies for ulcerative colitis, we do have choices. And you can use both that information ...

another. Patients that are more likely to go on to colectomy for ulcerative colitis vs. another high-risk patients, that we may have overlooked, or high-risk factors that we may have overlooked ...

If you’re living with ulcerative colitis, testing may help identify which foods bother you, so that you can cut them out of your diet. Ulcerative colitis (UC) cannot cause a food allergy ...